



LYMPHOMA RESEARCH FOUNDATION

Consolidated Financial Statements

June 30, 2017 and 2016

(With Independent Auditors' Report Thereon)



KPMG LLP
345 Park Avenue
New York, NY 10154-0102

Independent Auditors' Report

The Board of Directors
Lymphoma Research Foundation:

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Lymphoma Research Foundation (the Foundation), which comprise the consolidated balance sheets as of June 30, 2017 and 2016, and the related consolidated statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Lymphoma Research Foundation as of June 30, 2017 and 2016, and the changes in its net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

KPMG LLP

November 14, 2017

LYMPHOMA RESEARCH FOUNDATION

Consolidated Balance Sheets

June 30, 2017 and 2016

Assets	2017	2016
Cash and cash equivalents (note 3)	\$ 1,280,317	1,206,671
Contributions and grants receivable	477,038	288,769
Prepaid expenses and other assets	419,543	323,883
Investments (note 3)	9,860,774	8,711,525
Property and equipment, net (note 4)	637,083	49,060
Total assets	<u>\$ 12,674,755</u>	<u>10,579,908</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses (note 7)	\$ 577,445	173,537
Accrued salaries and vacation	211,677	187,244
Refundable advances	135,000	95,000
Research grants payable (note 5)	2,984,670	2,505,920
Total liabilities	<u>3,908,792</u>	<u>2,961,701</u>
Commitments (note 7)		
Net assets:		
Unrestricted	3,101,129	2,574,349
Temporarily restricted (note 8)	5,664,834	5,043,858
Total net assets	<u>8,765,963</u>	<u>7,618,207</u>
Total liabilities and net assets	<u>\$ 12,674,755</u>	<u>10,579,908</u>

See accompanying notes to consolidated financial statements.

LYMPHOMA RESEARCH FOUNDATION

Consolidated Statements of Activities

Years ended June 30, 2017 and 2016

	2017	2016
Change in unrestricted net assets:		
Contributions and revenue:		
Contributions:		
Special events revenue and related contributions	\$ 2,881,842	3,153,680
Less costs of direct benefits to donors	(178,520)	(187,925)
Contributions and grants	4,230,053	3,114,179
Total contributions	6,933,375	6,079,934
Revenue:		
Investment income (note 3)	45,566	75,451
Other revenue	30,787	21,657
Total revenue	76,353	97,108
Total contributions and revenue before net assets released from restrictions	7,009,728	6,177,042
Net assets released from restrictions (note 8)	3,772,387	4,296,290
Total contributions and revenue	10,782,115	10,473,332
Expenses:		
Program services:		
Educational programs and patient services	2,526,498	2,835,795
Research	3,620,776	3,816,157
Communications and advocacy	1,533,206	1,288,050
Total program services	7,680,480	7,940,002
Supporting services:		
Administration	503,515	371,052
Fundraising	2,071,340	1,786,269
Total supporting services	2,574,855	2,157,321
Total expenses	10,255,335	10,097,323
Increase in unrestricted net assets	526,780	376,009
Change in temporarily restricted net assets:		
Contributions and grants	4,393,363	4,450,785
Net assets released from restrictions (note 8)	(3,772,387)	(4,296,290)
Increase in temporarily restricted net assets	620,976	154,495
Change in net assets	1,147,756	530,504
Net assets at beginning of year	7,618,207	7,087,703
Net assets at end of year	\$ 8,765,963	7,618,207

See accompanying notes to consolidated financial statements.

LYMPHOMA RESEARCH FOUNDATION

Consolidated Statement of Functional Expenses

Year ended June 30, 2017

	Program services				Supporting services			Total 2017
	Educational programs and patient services	Research	Communications and advocacy	Total program services	Administration	Fundraising	Total supporting services	
Grants (note 5)	\$ 120,900	1,800,000	—	1,920,900	—	—	—	1,920,900
Salaries	743,714	322,839	417,494	1,484,047	196,070	821,466	1,017,536	2,501,583
Payroll taxes and employee benefits	198,112	85,999	111,662	395,773	52,230	222,301	274,531	670,304
Conferences and events	675,410	293,633	31,078	1,000,121	21,230	200,158	221,388	1,221,509
Costs of direct benefits to donors	—	—	—	—	—	178,520	178,520	178,520
Dues and subscriptions	4,162	21,620	31,709	57,491	7,135	24,059	31,194	88,685
Insurance	7,270	3,156	4,081	14,507	1,917	8,030	9,947	24,454
Licenses and permits	303	131	170	604	155	17,249	17,404	18,008
Marketing and promotion	49,132	17,457	556,059	622,648	155	31,902	32,057	654,705
Processing fees and other	17,301	7,708	12,416	37,425	4,223	146,647	150,870	188,295
Office equipment	15,203	2,793	6,437	24,433	1,696	51,249	52,945	77,378
Office supplies	22,111	7,676	4,948	34,735	2,598	17,435	20,033	54,768
Postage and shipping	44,605	16,251	4,072	64,928	1,064	42,737	43,801	108,729
Printing and publications	79,558	29,157	12,085	120,800	1,637	48,655	50,292	171,092
Professional fees	142,399	776,355	166,048	1,084,802	143,459	108,368	251,827	1,336,629
Rent (note 7)	161,752	70,215	90,801	322,768	42,644	178,662	221,306	544,074
Repairs and maintenance	48,639	21,114	27,304	97,057	12,823	57,324	70,147	167,204
Telecommunications	87,967	5,324	7,179	100,470	3,233	14,382	17,615	118,085
Travel	97,486	134,801	43,783	276,070	8,485	69,147	77,632	353,702
Depreciation and amortization	10,474	4,547	5,880	20,901	2,761	11,569	14,330	35,231
Subtotal	2,526,498	3,620,776	1,533,206	7,680,480	503,515	2,249,860	2,753,375	10,433,855
Less direct donor benefit expenses	—	—	—	—	—	(178,520)	(178,520)	(178,520)
Total expenses	\$ 2,526,498	3,620,776	1,533,206	7,680,480	503,515	2,071,340	2,574,855	10,255,335

See accompanying notes to consolidated financial statements.

LYMPHOMA RESEARCH FOUNDATION

Consolidated Statement of Functional Expenses

Year ended June 30, 2016

	Program services				Supporting services			Total 2016
	Educational programs and patient services	Research	Communications and advocacy	Total program services	Administration	Fundraising	Total supporting services	
Grants (note 5)	\$ 163,250	1,670,000	—	1,833,250	—	—	—	1,833,250
Salaries	814,424	359,207	395,625	1,569,256	180,431	700,206	880,637	2,449,893
Payroll taxes and employee benefits	217,093	95,750	105,458	418,301	48,096	189,935	238,031	656,332
Conferences and events	832,391	421,666	10,342	1,264,399	10,483	202,763	213,246	1,477,645
Costs of direct benefits to donors	—	—	—	—	—	187,925	187,925	187,925
Dues and subscriptions	2,957	18,912	33,240	55,109	254	2,986	3,240	58,349
Insurance	7,792	3,437	3,785	15,014	1,726	9,949	11,675	26,689
Licenses and permits	—	—	—	—	225	21,810	22,035	22,035
Marketing and promotion	141,896	29,337	456,494	627,727	205	38,907	39,112	666,839
Processing fees and other	14,477	2,609	1,141	18,227	15,556	148,312	163,868	182,095
Office equipment	15,754	3,100	3,414	22,268	1,557	47,249	48,806	71,074
Office supplies	19,870	5,006	2,879	27,755	1,253	17,341	18,594	46,349
Postage and shipping	57,775	13,006	2,267	73,048	296	49,603	49,899	122,947
Printing and publications	133,692	39,525	17,015	190,232	235	68,435	68,670	258,902
Professional fees	23,437	854,608	123,865	1,001,910	63,832	41,425	105,257	1,107,167
Rent (note 7)	139,988	61,743	68,002	269,733	31,014	120,356	151,370	421,103
Repairs and maintenance	28,785	12,696	13,983	55,464	6,377	28,348	34,725	90,189
Telecommunications	89,499	5,994	6,773	102,266	3,011	12,763	15,774	118,040
Travel	125,104	216,204	40,070	381,378	4,815	79,337	84,152	465,530
Depreciation and amortization	7,611	3,357	3,697	14,665	1,686	6,544	8,230	22,895
Subtotal	2,835,795	3,816,157	1,288,050	7,940,002	371,052	1,974,194	2,345,246	10,285,248
Less direct donor benefit expenses	—	—	—	—	—	(187,925)	(187,925)	(187,925)
Total expenses	\$ 2,835,795	3,816,157	1,288,050	7,940,002	371,052	1,786,269	2,157,321	10,097,323

See accompanying notes to consolidated financial statements.

LYMPHOMA RESEARCH FOUNDATION

Consolidated Statements of Cash Flows

Years ended June 30, 2017 and 2016

	2017	2016
Cash flows from operating activities:		
Change in net assets	\$ 1,147,756	530,504
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and amortization	35,231	22,895
Realized (gain) loss on investments	(122)	309
Unrealized loss (gain) on investments	50,021	(17,876)
Changes in operating assets and liabilities:		
Contributions and grants receivable	(188,269)	243,419
Prepaid expenses and other assets	(95,660)	(74,619)
Accounts payable and accrued expenses	403,908	(296,028)
Accrued salaries and vacation	24,433	(187,331)
Refundable advances	40,000	3,000
Research grants payable	478,750	(280,500)
Net cash provided by (used in) operating activities	1,896,048	(56,227)
Cash flows from investing activities:		
Proceeds from investment sales	2,949,158	6,618,762
Purchases of investments	(4,148,306)	(6,805,339)
Purchase of equipment	(623,254)	(44,815)
Net cash used in investing activities	(1,822,402)	(231,392)
Net increase (decrease) in cash and cash equivalents	73,646	(287,619)
Cash and cash equivalents at beginning of year	1,206,671	1,494,290
Cash and cash equivalents at end of year	\$ 1,280,317	1,206,671

See accompanying notes to consolidated financial statements.

LYMPHOMA RESEARCH FOUNDATION

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(1) Organization

The Lymphoma Research Foundation (the Foundation) is a nonprofit corporation, which is exempt from Federal income taxes under Internal Revenue Code Section 501(c)(3) and similar provisions at the state and local level. The Foundation is the nation's largest nonprofit organization devoted to only funding innovative lymphoma research and providing patients and their families and healthcare professionals with up-to-date education about this type of cancer. The Foundation's mission is to eradicate lymphoma and serve those touched by this disease. The Foundation's primary sources of income are contributions and grants.

To help ensure that the amounts the Foundation raises is directed toward cutting-edge lymphoma-related research, decisions of what research will be funded are made by the deliberations of the Foundation's Scientific Advisory Board (SAB). The SAB comprises a volunteer group of scientists and clinicians distinguished in the fields of lymphoma research and treatment. They make their judgments on applications for funding based on the scientific and innovative merits of the projects proposed, the demonstrated ability of the researcher and sponsor, and the suitability of the institution. The members of the SAB review the applications independently and then meet to discuss the proposals at periodic meetings scheduled throughout the year.

In addition to evaluating grant applications, the SAB counsels the Foundation's board of directors and staff on the direction of its overall strategic scientific agenda in order to remain current with the pace and direction of the rapidly evolving area of blood cancer research.

The board of directors studies the recommendations of the SAB. Its aim is to approve those recommended grant applications and projects that seem most likely to have an impact on lymphoma-related research and treatments, and therefore most likely to help the Foundation achieve its overall goals. The Foundation funds research projects submitted by individuals associated with accredited academic institutions, Joint Commission on Accreditation of Healthcare Organizations, accredited research hospitals, and other research organizations that have strong national and international reputations.

The Foundation is also dedicated to serving those touched by lymphoma. To accomplish this, the Foundation provides national, regional, and local educational conferences and symposiums, advocacy programs, online Webcast educational programming, telephone educational workshops, and educational publications. The Foundation's educational programs and publications provide lymphoma patients and their loved ones with current and comprehensive information about the disease, its treatments, promising research in lymphoma, and how to better manage the psycho/social issues associated with living with lymphoma. The Foundation also offers a Lymphoma Helpline and Clinical Trials Information Service, a nationwide peer support program, and financial assistance to lymphoma patients receiving treatment.

The Foundation entered into a strategic relationship with the Clarus Cancer Fund (Cancer Fund) an investment fund of Clarus Ventures, an established life sciences venture capital firm and leader in cancer investments. The Cancer Fund will further its scientific impact by donating a significant amount of its net investment profits to the Foundation to substantially increase its research budget.

In connection with the Cancer Fund, during fiscal year 2017, the Foundation established a new subsidiary, LRF Research Inc. (LRF Research) to receive certain annual payments from Clarus or the general partner of the Cancer Fund, and entered into an intellectual property license and administrative services agreement with LRF Research. Such agreement provides for license fees to be paid by LRF Research to the

LYMPHOMA RESEARCH FOUNDATION

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

Foundation with respect to certain intellectual property licensed to LRF Research and certain administrative fees to be payable by LRF Research to the Foundation with respect to the cost of certain services to be provided by the Foundation.

(2) Summary of Significant Accounting Policies

(a) *Basis of Presentation*

The Foundation's financial statements have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles. Net assets and the changes therein are classified and reported as follows:

Unrestricted – Net assets that are not subject to donor-imposed restrictions

Temporarily Restricted – Net assets subject to donor-imposed restrictions that will be met by actions of the Foundation and/or the passage of time

Revenue is reported as increases in unrestricted net assets unless their use is limited by explicit donor-imposed restrictions or by law. Expenses are reported as decreases in net assets.

The Foundation's financial statements include the accounts of the LRF, Inc., eliminating intercompany transactions.

(b) *Accounting Estimates*

The preparation of the financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the financial statements and revenue and expenses recognized during the reporting period. Significant estimates made in the preparation of the financial statements include the net realizable value of contributions and grants receivable, the valuation of contributed services, and functional expense allocations. Actual results could differ from those estimates.

(c) *Fair Value*

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs for the asset or liability.

LYMPHOMA RESEARCH FOUNDATION
Notes to Consolidated Financial Statements
June 30, 2017 and 2016

(d) Contributions

Contributions, including unconditional promises to give (pledges), are recognized initially at fair value as revenue upon receipt and are considered to be unrestricted unless they are received with donor stipulations that limit their use through either purpose or time restrictions. Contributions with donor stipulations that limit their use are considered to be temporarily restricted until the donor restrictions expire, that is, when a time restriction ends or purpose restriction is fulfilled. Upon the expiration of donor stipulations, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the accompanying consolidated statements of activities as net assets released from restrictions.

During the years ended June 30, 2017 and 2016, the Foundation received \$1,233,224 and \$1,202,408, respectively, in contributions in kind that are reported as contributions and expenses in the accompanying consolidated statements of activities and functional expenses. The 2017 and 2016 amounts include \$482,374 and \$379,508, respectively, recognized in revenues and expenses from Google grants. The 2017 and 2016 amounts also include \$750,850 and \$822,900, respectively, recognized in revenues and expenses associated with the recognition of time spent by SAB members to carry out the requirements of its research program as well as support the Foundation's professional and patient education programs. Without the volunteer support these physicians provide the Foundation, the organization would be required to compensate physicians to perform these services.

A substantial number of other volunteers have donated significant amounts of their time in supporting the Foundation's activities. No amounts have been reflected in the accompanying consolidated financial statements for these donated services since they do not meet the criteria for recognition.

Contributions and grants receivable of \$477,038 as of June 30, 2017 are scheduled to be collected within a year.

(e) Cash and Cash Equivalents

The Foundation considers all highly liquid investments with an original maturity of 90 days or less when acquired to be cash equivalents, with the exception of cash and those short-term investments that are maintained in the Foundation's investment portfolio.

(f) Investments

Investments are reported at fair value based upon quoted market prices.

(g) Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on the straight-line basis over the estimated useful lives of the assets ranging from two to five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful lives or the term of the lease. The Foundation capitalizes all property and equipment having a cost of \$1,000 or more and a useful life of at least two years.

LYMPHOMA RESEARCH FOUNDATION
Notes to Consolidated Financial Statements
June 30, 2017 and 2016

(h) Refundable Advances

Amounts received by the Foundation for certain special events are reflected as refundable advances until the event occurs. The majority of these amounts are characterized by the Foundation as an exchange transaction.

(i) Functional Expense Allocations

The costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

(j) Income Taxes

The Foundation recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Income generated from activities unrelated to the Foundation's exempt purpose is subject to tax under Internal Revenue Code Section 511. The Foundation did not recognize any unrelated business income tax liability for the year ended June 30, 2017 or 2016.

(3) Investments

The following tables present the Foundation's fair value hierarchy for investments measured at fair value as of June 30, 2017 and 2016:

	2017		
	Total	Level 1	Level 2
Investments:			
Money market fund	\$ 93,521	93,521	—
Certificates of deposit	9,767,253	—	9,767,253
Total investments	<u>\$ 9,860,774</u>	<u>93,521</u>	<u>9,767,253</u>
	2016		
	Total	Level 1	Level 2
Investments:			
Money market fund	\$ 194,401	194,401	—
Certificates of deposit	8,517,124	—	8,517,124
Total investments	<u>\$ 8,711,525</u>	<u>194,401</u>	<u>8,517,124</u>

LYMPHOMA RESEARCH FOUNDATION
Notes to Consolidated Financial Statements
June 30, 2017 and 2016

Investment income consists of the following for the years ended June 30, 2017 and 2016:

	<u>2017</u>	<u>2016</u>
Interest and dividends	\$ 95,465	57,884
Realized gain (loss) on investments	122	(309)
Unrealized (loss) gain on investments	<u>(50,021)</u>	<u>17,876</u>
	<u>\$ 45,566</u>	<u>75,451</u>

The Foundation maintains cash and cash equivalents in major financial institutions. Investments that are described above include certificates of deposit (CDs) having original maturities greater than 90 days. The CDs are maintained at a number of financial institutions. As of June 30, 2017, there was no exposure of credit risk that exceeded the Federal Deposit Insurance Corporation insurance limits for both cash and cash equivalents and CDs.

(4) Property and Equipment

Property and equipment includes the following as of June 30, 2017 and 2016:

	<u>June 30</u>	
	<u>2017</u>	<u>2016</u>
Furnitures and office equipment	\$ 306,193	76,346
Computer equipment and software	360,742	78,400
Leasehold improvements	<u>121,101</u>	<u>10,036</u>
Property and equipment	788,036	164,782
Less accumulated depreciation and amortization	<u>(150,953)</u>	<u>(115,722)</u>
Property and equipment, net	<u>\$ 637,083</u>	<u>49,060</u>

(5) Research and Patient Aid Grants

Research grant expense is recorded when the grant is approved by the Foundation and the grantee is notified of the award. Research grants are generally awarded for a two-to three-year period, with payments made quarterly.

The Foundation offers a financial assistance program for people currently undergoing treatment for lymphoma. Patient aid grants assist with quality of life expenses.

LYMPHOMA RESEARCH FOUNDATION
Notes to Consolidated Financial Statements
June 30, 2017 and 2016

The following provides grant activity for fiscal years 2017 and 2016:

	<u>2017</u>	<u>2016</u>
Grants payable, beginning of year	\$ 2,505,920	2,786,420
Grants awarded	1,920,900	1,833,250
Grant payments and cancellations	<u>(1,442,150)</u>	<u>(2,113,750)</u>
Grant payable, end of year	<u>\$ 2,984,670</u>	<u>2,505,920</u>

Grants payable are scheduled to be paid as follows as of June 30, 2017 and 2016:

	<u>2017</u>	<u>2016</u>
Amount payable in one year or less	\$ 1,444,670	1,135,920
Amount payable in one to five years	<u>1,540,000</u>	<u>1,370,000</u>
	<u>\$ 2,984,670</u>	<u>2,505,920</u>

(6) Pension Plan

The Foundation maintains a retirement plan pursuant to Internal Revenue Code Section 403(b) for its employees. Employees are eligible to participate immediately. Under the terms of the plan, employees are entitled to defer a portion of their annual compensation, within limitations established by the Internal Revenue Code. During 2006, the Foundation started a matching program whereby it contributes an amount equal to 5% of annual compensation for eligible employees provided that the employees contributes at least 3% to the plan. Retirement expense under the plan amounted to \$97,000 and \$88,000 for the years ended June 30, 2017 and 2016, respectively.

(7) Commitments

The Foundation has lease agreements for the rental of its New York and California offices. The Foundation's long-term lease, at 115 Broadway, New York, NY 10006 expired at July 31, 2017. The Foundation entered into a new ten-year lease agreement at 88 Pine Street, New York, NY 10005 effective March 17, 2017. Additionally, the lease on the California office expired October 31, 2017 and was not renewed.

LYMPHOMA RESEARCH FOUNDATION
Notes to Consolidated Financial Statements
June 30, 2017 and 2016

Minimum annual rentals related to these leases are approximately as follows for the years ended subsequent to June 30, 2017:

2018	\$	402,572
2019		357,194
2020		357,194
2021		357,194
2022		365,774
Thereafter		<u>2,030,448</u>
	\$	<u><u>3,870,376</u></u>

The Foundation leases its New York City office whereby the landlord has provided periods of free rent. The Foundation recorded a liability for this free rent that it amortizes on a straight-line basis over the life of the lease. Included in accounts payable and accrued expenses is deferred rent of \$104,181 as of June 30, 2017.

Rent expense for the years ended June 30, 2017 and 2016 amounted to approximately \$544,000 and \$421,000, respectively.

(8) Temporarily Restricted Net Assets

Temporarily restricted net assets are available for the following as of June 30, 2017 and 2016:

	<u>2017</u>	<u>2016</u>
Research program	\$ 1,645,689	1,671,219
Patient and professional programs	4,016,698	3,349,008
Patient aid	<u>2,447</u>	<u>23,631</u>
	<u>\$ 5,664,834</u>	<u>5,043,858</u>

Net assets were released from restrictions during the years ended June 30, 2017 and 2016 by incurring expenses or the passage of time, thus satisfying the restricted purposes as follows:

	<u>2017</u>	<u>2016</u>
Research program	\$ 2,113,176	2,184,184
Patient and professional programs	1,524,311	1,948,856
Patient aid	<u>134,900</u>	<u>163,250</u>
	<u>\$ 3,772,387</u>	<u>4,296,290</u>

LYMPHOMA RESEARCH FOUNDATION
Notes to Consolidated Financial Statements
June 30, 2017 and 2016

(9) Subsequent Events

In connection with the preparation of the consolidated financial statements, the Foundation evaluated subsequent events after the consolidated balance sheet date of June 30, 2017 through November 14, 2017, which was the date the consolidated financial statements were available to be issued and determined that there were no additional matters that are required to be disclosed.